NCT02207439View on ClinicalTrials.gov

Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2022

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nelfinavir (Viracept®) 1250 mg

Period 1: Nelfinavir Lead-In (1250 mg bid, 7-14 days).

OTHER

Chemoradiation

Period 2: Concurrent Chemoradiation (70 Gy over 7 weeks) with Nelfinavir (1250 mg bid)

Trial Locations (1)

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02207439 - Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter